Diffusion-weighted magnetic resonance imaging is useful for the response evaluation of chemotherapy and/or radiotherapy to recurrent lesions of lung cancer.
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
15
12
2018
revised:
12
02
2019
accepted:
14
02
2019
pubmed:
12
3
2019
medline:
12
3
2019
entrez:
12
3
2019
Statut:
ppublish
Résumé
Diffusion-weighted magnetic resonance imaging (DWI) has been reported to be useful for the assessment of lung cancer staging. It is uncertain whether DWI is more accurate for the response evaluation of chemotherapy and/or radiotherapy compared to computed tomography (CT). The purpose of this study is to compare the response evaluation of DWI for chemotherapy and/or radiotherapy to recurrent tumors of lung cancer with that of CT which is a standard tool in RECIST (Response Evaluation Criteria in Solid Tumours). Forty-one patients who agreed to this project and had CT scan and DWI examinations within a month of each other every six months for at least 2 years after pulmonary resection of primary lung cancer were enrolled in this study. Of the patients, 24 patients had metastases or recurrences, and CT and DWI were performed for assessment of the response evaluation of chemotherapy and/or radiotherapy to recurrent lesions. They were followed up for at least two years after the relapse. The response evaluation by CT using RECIST were PR in five patients, SD in two, and PD in the remaining 17 patients. On the other hand, the response evaluation by DWI were CR in four patients, PR in two patients, SD in one, and PD in the remaining 17 patients. Follow-up studies revealed the response evaluation by DWI were correct. Functional evaluation of DWI is better than that of CT for the response evaluation of chemotherapy and/or radiotherapy to recurrent tumors of lung cancer.
Identifiants
pubmed: 30856554
pii: S1936-5233(18)30630-2
doi: 10.1016/j.tranon.2019.02.005
pmc: PMC6411607
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
699-704Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Références
AJNR Am J Neuroradiol. 1999 Aug;20(7):1252-7
pubmed: 10472982
AJR Am J Roentgenol. 2007 Apr;188(4):1001-8
pubmed: 17377036
J Thorac Oncol. 2008 Apr;3(4):358-64
pubmed: 18379353
Eur J Radiol. 2008 Nov;68(2):289-98
pubmed: 18799279
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
J Nucl Med. 2010 Oct;51(10):1549-58
pubmed: 20847177
Br J Radiol. 2012 May;85(1013):577-86
pubmed: 21343320
NMR Biomed. 2011 Dec;24(10):1181-90
pubmed: 21387451
Ann Thorac Surg. 2011 Jun;91(6):1689-95
pubmed: 21619964
Eur Radiol. 2012 Jan;22(1):18-25
pubmed: 21845462
Radiology. 2011 Nov;261(2):598-604
pubmed: 21852569
Jpn J Radiol. 2012 Feb;30(2):120-7
pubmed: 22173559
AJR Am J Roentgenol. 2012 Jan;198(1):75-82
pubmed: 22194481
Crit Rev Oncol Hematol. 2012 Aug;83(2):194-207
pubmed: 22269446
Radiol Oncol. 2011 Jun;45(2):91-6
pubmed: 22933941
Ann Surg Oncol. 2013 May;20(5):1676-83
pubmed: 23242821
Radiol Oncol. 2013 Jul 30;47(3):206-18
pubmed: 24133384
Acad Radiol. 2014 Jan;21(1):21-9
pubmed: 24331261
Asian Pac J Cancer Prev. 2014;15(11):4629-35
pubmed: 24969896
Eur Radiol. 2016 Feb;26(2):556-66
pubmed: 26003791
Lung Cancer. 2015 Dec;90(3):433-41
pubmed: 26443279
AJR Am J Roentgenol. 2016 Feb;206(2):283-90
pubmed: 26587799
Radiology. 2016 Oct;281(1):86-98
pubmed: 27110732
AJR Am J Roentgenol. 2016 Oct;207(4):804-810
pubmed: 27490448
Radiology. 1988 Aug;168(2):497-505
pubmed: 3393671
AJR Am J Roentgenol. 1994 Mar;162(3):671-7
pubmed: 8109520
Magn Reson Imaging. 1996;14(9):1113-6
pubmed: 9071004